Skip to content

Study · Systematic review · n = 726 · 2021

2 results

Intranasal oxytocin in the treatment of autism spectrum disorders: A multilevel meta-analysis.

Huang Y, Huang X, Ebstein RP, Yu R

Neuroscience and biobehavioral reviews2 Jan 2021Cited by 102 (Europe PMC)

PMID33400920 (opens in a new tab)DOI10.1016/j.neubiorev.2020.12.028 (opens in a new tab)PepBankPUB-33400920
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with autism spectrum disorder, a multilevel meta-analysis found that intranasal oxytocin had beneficial effects on social functioning.

    In plain wordsIn people with autism, nasal oxytocin had beneficial effects on social functioning in a meta-analysis.

    Peptide
    Oxytocin
    Outcome
    IncreaseSocial functioning in ASD
    Study

    n = 726

    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    oxytocin had beneficial effects on social functioning, but did not find strong evidence for symptoms improvement in the non-social domain.
    2 context sentences
    Summary · context
    We performed a systematic literature search, including randomized, single- or double-blind/open-label and placebo-controlled clinical trials as well as single-arm, non-randomized and uncontrolled studies investigating exogenous oxytocin effect on ASD.
    Summary · context
    A total of 28 studies (N = 726 ASD patients) met our predefined inclusion criteria.
  2. 02HumanSystematic reviewEfficacy outcome

    In patients with autism spectrum disorder, the meta-analysis found no strong evidence that intranasal oxytocin improved symptoms in the non-social domain.

    In plain wordsIn people with autism, nasal oxytocin showed no strong evidence of improving symptoms outside social functioning.

    Peptide
    Oxytocin
    Outcome
    No significant changeNon-social symptoms in ASD
    Study

    n = 726

    Outcome group
    Autism core symptoms · Mental health and mood
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    did not find strong evidence for symptoms improvement in the non-social domain.
    2 context sentences
    Summary · context
    We performed a systematic literature search, including randomized, single- or double-blind/open-label and placebo-controlled clinical trials as well as single-arm, non-randomized and uncontrolled studies investigating exogenous oxytocin effect on ASD.
    Summary · context
    A total of 28 studies (N = 726 ASD patients) met our predefined inclusion criteria.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.